WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsTransMedics Group Inc (TMDX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 3306% more annual revenue ($20.63B vs $605.49M). TMDX leads profitability with a 31.4% profit margin vs 10.1%. GEHC trades at a lower P/E of 15.6x. TMDX earns a higher WallStSmart Score of 64/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

TMDX

Buy

64

out of 100

Grade: C+

Growth: 8.7Profit: 8.0Value: 8.3Quality: 7.5
Piotroski: 4/9Altman Z: 1.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued
TMDXUndervalued (+41.5%)

Margin of Safety

+41.5%

Fair Value

$227.92

Current Price

$105.13

$122.79 discount

UndervaluedFair: $227.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

TMDX3 strengths · Avg: 10.0/10
Return on EquityProfitability
54.2%10/10

Every $100 of equity generates 54 in profit

Profit MarginProfitability
31.4%10/10

Keeps 31 of every $100 in revenue as profit

Revenue GrowthGrowth
32.2%10/10

Revenue surging 32.2% year-over-year

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

TMDX2 concerns · Avg: 2.5/10
Debt/EquityHealth
1.463/10

Elevated debt levels

Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : TMDX

The strongest argument for TMDX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 13.2%. Revenue growth of 32.2% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : TMDX

The primary concerns for TMDX are Debt/Equity, Altman Z-Score.

Key Dynamics to Monitor

GEHC profiles as a value stock while TMDX is a growth play — different risk/reward profiles.

TMDX carries more volatility with a beta of 1.96 — expect wider price swings.

TMDX is growing revenue faster at 32.2% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

TMDX scores higher overall (64/100 vs 60/100), backed by strong 31.4% margins and 32.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

TransMedics Group Inc

HEALTHCARE · MEDICAL DEVICES · USA

TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?